Baricitinib (Olumiant), developed by Eli Lilly, is a selective Janus kinase (JAK) 1/2 inhibitor approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) and other inflammatory conditions. The drug has also gained attention for emergency use in COVID-19 patients with severe diseas...Read More »
October 20, 2025
The global cosmetics industry is projected to demonstrate sustained growth through 2032, driven by evolving consumer expectations, technological advancements, and an increasing alignment of beauty with wellness and sustainability. Across major economies, including China, the U.S, Germany, France, ...Read More »
October 20, 2025
Rituximab (Rituxan), developed by Roche, is a chimeric monoclonal antibody targeting CD20, widely used in the treatment of B-cell malignancies such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, as well as autoimmune disorders including rheumatoid arthritis. Approved in over 100...Read More »
October 20, 2025
The drug discovery and development landscape is undergoing a paradigm shift, driven by the convergence of multiomics technologies including genomics, transcriptomics, proteomics, metabolomics, and epigenomics. These integrative approaches provide a comprehensive molecular understanding of disease ...Read More »
October 20, 2025
The exosome diagnostics and therapeutics industry is transforming as scientific understanding of extracellular vesicles deepens and their clinical potential becomes increasingly evident. Exosomes, which were formerly thought of as cellular waste, are now understood to be potent biological messenge...Read More »
October 20, 2025
Aducanumab, marketed as Aduhelm, is an amyloid-beta–targeting monoclonal antibody developed by Biogen Inc. in partnership with Eisai Co., Ltd. for the treatment of Alzheimer’s disease. It works by binding to aggregated amyloid-beta proteins and facilitating their removal from the brain...Read More »
October 17, 2025
Botulinum Toxin A, including leading brands such as Botox (Allergan), Dysport (Ipsen), and Xeomin (Merz), is a widely used neurotoxin therapy with applications spanning both therapeutic and aesthetic indications. Therapeutically, it addresses chronic migraine, spasticity, cervical dystonia, and hy...Read More »
October 17, 2025
The general surgery devices market is undergoing a period of rapid consolidation. Leading medical device companies have strategically acquired innovative companies in order to enhance their product offerings and competitive advantage in the post-pandemic healthcare environment. Deal activity has s...Read More »
October 17, 2025
Skin boosters are different from conventional dermal fillers in that they target skin hydration, increase elasticity, diminish fine lines, and help improve overall skin texture. They stimulate collagen development and promote skin cell metabolism and are additionally effective for dehydrated, agin...Read More »
October 16, 2025
The kidney disorder management devices industry is evolving with innovations in wearable dialysis, AI-driven systems, and remote monitoring. Emerging technologies enhance patient mobility, and home-based care. These advancements address the growing prevalence of CKD, improve outcomes, and open new...Read More »
October 16, 2025
Vedolizumab (Entyvio), developed by Takeda Pharmaceuticals, is a leading gut-selective α4β7 integrin antagonist used for treating inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Approved in over 70 countries, the drug is also under re...Read More »
October 16, 2025
Denosumab, marketed by Amgen under the brand names Prolia and Xgeva, is a fully human monoclonal antibody that inhibits RANK ligand (RANKL) to suppress osteoclast formation and bone resorption. Prolia is prescribed for osteoporosis and bone loss associated with hormonal therapy, administered as a ...Read More »
October 15, 2025
Tocilizumab (Actemra), developed by Roche, is a leading interleukin-6 (IL-6) inhibitor used for treating autoimmune diseases like rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS). Approved in over 100 countries, the drug is also under regulatory rev...Read More »
October 15, 2025
Insulin Degludec (Tresiba), developed by Novo Nordisk, is a leading ultra-long-acting basal insulin used for managing type 1 and type 2 diabetes. Approved in over 80 countries, Tresiba offers a flexible dosing schedule, extended 42-hour action, and reduced risk of hypoglycemia, making it a preferr...Read More »
October 14, 2025
Darolutamide (Nubeqa) and Enzalutamide (Xtandi) are androgen receptor inhibitors in prostate cancer treatment. Darolutamide, developed by Bayer and Orion, is protected by U.S. patents with generic entry estimated in 2038. It is approved in over 80 markets globally and is under regulatory review fo...Read More »
October 14, 2025
Mobility disability refers to any condition that restricts or impairs a person's ability to move freely or carry out physical activities independently. Assistive devices like wheelchairs, walkers, prosthetic limbs, and white canes are vital tools that support individuals with mobility challenges c...Read More »
October 13, 2025
Remdesivir (Veklury) market remains stable but has transitioned from pandemic-driven demand to a more selective therapeutic use profile. Its utilization is largely concentrated in hospital settings for managing severe COVID-19 cases and select viral infections under investigation. While global dem...Read More »
October 13, 2025
Influenza A and B continue to impose a significant global health and economic burden each year, driving the need for fast, accurate, and accessible diagnostic solutions. The diagnostics landscape for influenza has undergone a profound transformation in recent years, evolving from conventional anti...Read More »
October 13, 2025
The U.S. medical claims market is one of the largest transactional ecosystems in the world, processing over 10 billion medical claims annually. The rising utilization of healthcare, fueled by an aging population and the increasing prevalence of chronic diseases, has led to an increase in the numbe...Read More »
October 13, 2025
Ibrutinib, marketed as Imbruvica by AbbVie and Janssen, has become a cornerstone treatment in oncology, particularly for hematologic malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The drug has delivered strong market performance due to its proven efficacy i...Read More »
October 13, 2025